EBO2 (EBOO) vs Plasmapheresis: Similar Machines, Very Different Medicine

EBO2 (also called EBOO) and plasmapheresis both work by drawing a patient’s blood into a machine and returning it, which is why clinics sometimes mention them in the same sentence. The resemblance stops at the plumbing. Plasmapheresis is an established, FDA-regulated hospital procedure with graded indications built from decades of controlled study, while EBO2 is neither regulated as a plasma-separation therapy nor supported by comparable evidence for any disease. For the fuller procedure description, see the pillar guide on what EBO2 is.

What plasmapheresis is and what it is approved for

Plasmapheresis is the process of separating plasma from the rest of the blood; when the separated plasma is discarded and replaced with a substitute fluid, the procedure is usually called plasma exchange or therapeutic plasma exchange (TPE) [1]. A clinician inserts an IV line, gradually removes blood, runs it through a machine that separates plasma from blood cells, discards the plasma, combines the remaining blood with a replacement fluid such as albumin, and returns it, in a session that can take several hours [1]. It is used for a range of blood, neurologic, and autoimmune conditions, including multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, cryoglobulinemia, and certain blood cancers [1]. The American Society for Apheresis (ASFA) maintains a standing writing committee that reviews the evidence for therapeutic apheresis and publishes it as 84 disease-specific fact sheets, each with a graded, categorized indication built on a systematic review methodology introduced in 2007 [2]. That grading system is why a hospital can tell a referring physician, with a specific evidence category attached, whether plasma exchange is an appropriate first-line treatment for a given diagnosis.

The specific conditions on that list illustrate how narrow and deliberate evidence-graded practice actually is. Myasthenia gravis, an autoimmune disease that weakens muscles by disrupting nerve signaling, and Guillain-Barre syndrome, an autoimmune attack on peripheral nerves that can progress toward paralysis, are both conditions in which antibodies circulating in plasma are believed to drive the disease, which is why removing and replacing plasma has a plausible, testable mechanism behind it [1]. Cryoglobulinemia, in which abnormal proteins clump together in cold temperatures and damage small blood vessels, is treated on the same logic: a specific protein carried in plasma is doing measurable harm, and plasma exchange removes it directly [1]. In every one of these cases, the claim is narrow and mechanistic, a defined molecule in plasma is causing a defined problem, rather than a broad claim about detoxification or immune support in general.

What EBO2 is and what it is not

EBO2 draws blood from one arm, passes it through a hollow-fiber hemofilter and a gas exchange device where it is exposed to an oxygen and ozone mixture, and returns it through the other arm in a continuous circuit lasting about an hour. The technique’s developers describe the filtration step as incidental to the ozone exposure, intended to keep the circuit running smoothly, rather than as a therapy in its own right comparable to plasma separation [4]. The rationale in the original technique papers is about ozone dose and exposure time, not about removing a specific harmful molecule: continuous filtration is described as a way to expose a larger fraction of the blood volume to a controlled ozone dose in a single session, compared with the smaller batches used in major autohemotherapy [4]. That is a claim about how the ozone is delivered, not a claim that the filter itself is the active ingredient the way plasma separation is for plasmapheresis. Nothing in the EBOO literature quantifies a plasma component that is removed and replaced the way plasma exchange removes and replaces plasma. EBO2 is not classified, cleared, or approved by the FDA as an apheresis device, and it is not administered for any of the evidence-graded indications that apply to plasmapheresis.

Why the evidence timelines look so different

Plasmapheresis and EBO2 also differ in how their evidence was built over time, which is part of why one has graded indications and the other does not. The ASFA writing committee has published eight editions of its special issue, the most recent building on a systematic, evidence-based review methodology the committee introduced in its fourth edition in 2007, and continuing to add, reclassify, and sometimes downgrade indications as new trial data appears [2]. That is an ongoing, structured, multi-decade review process involving a standing committee of specialists across multiple institutions. EBOO’s evidence base, by contrast, originates almost entirely from one research group’s publications between 2000 [9] and 2007 [10], capped by a single 28-patient randomized trial [11], with no comparable standing review process ever established for it, a history covered in full in a companion guide on whether EBO2 works. The difference in regulatory and clinical standing between the two procedures traces directly back to this difference in how, and for how long, each one’s evidence has actually been examined.

Side-by-side comparison

	Plasmapheresis (TPE)	EBO2
What is removed	Plasma, separated by centrifugation or membrane filtration [1]	Nothing quantified in a controlled study; blood passes through a filter incidentally to ozone exposure
What is replaced	Albumin, donor plasma, or another replacement fluid [1]	Nothing; the same blood is returned
Device regulation	Automated blood cell separators are FDA Class II devices under special controls [3]	No comparable FDA device classification for EBO2 systems
Evidence base	84 graded disease indications from a standing evidence review committee [2]	No controlled trials for any disease; see a companion guide on whether EBO2 works
Typical setting	Hospital or dedicated apheresis unit, sometimes outpatient	Integrative or functional medicine clinic
Typical cost	Billed through insurance for approved indications	Out of pocket; see the EBO2 cost guide

Why clinics borrow dialysis language

Some EBO2 marketing calls the procedure “ozone dialysis,” and at least one clinic lists “recirculatory hemoperfusion” as another name for it, pointing to the fact that blood is passed through a dialysis-type membrane during treatment [6]. Another clinic describes EBO2 as detoxing several liters of blood in a single session [5]. The comparison rests entirely on the equipment: a hollow-fiber cartridge that looks and is manufactured like a dialysis filter. It does not describe a shared clinical function. Kidney dialysis removes small waste molecules that a failing kidney cannot clear, and plasma exchange removes a defined blood component and replaces it; neither of these mechanisms has been quantified for EBO2 in a controlled study, a question addressed in more detail in a companion guide on what the EBO2 filter removes.

A patient reading “ozone dialysis” on a clinic website could reasonably assume the procedure has been tested and validated the way kidney dialysis has been, since dialysis is one of the most thoroughly studied procedures in medicine, developed and refined over roughly seven decades of clinical use. Borrowing that word for a one-hour ozone session that has not undergone anything close to that scrutiny transfers a sense of established, tested medicine onto a procedure that has not earned it through the same process. Renaming a machine does not change what has, and has not, been measured about what it does.

Risks compared

Plasmapheresis is not risk-free. Because it is performed in a hospital or dedicated apheresis unit under the indications reviewed by ASFA, its risks (low blood pressure, citrate reactions from the anticoagulant used to keep blood from clotting in the machine, infection at the access site, and reactions to replacement fluids such as albumin) are documented in the same evidence base that supports its use, and a clinician can weigh them against a graded benefit for a specific diagnosis [2]. A patient starting plasma exchange for Guillain-Barre syndrome is told, in advance, roughly how many sessions are typical, what the expected benefit is, and what the known complication rates look like, because that information has been collected across many patients over many years.

EBO2’s risks are less thoroughly documented because so little controlled research exists. A case report elsewhere in the ozone literature describes a patient on a related autohemotherapy procedure who developed a dangerous heart rhythm disturbance, sinus arrest, traced to a metabolic disturbance brought on by the treatment, though this case involved autohemotherapy rather than EBOO specifically [8]. What matters for a patient is whether a risk-benefit calculation has actually been done for the condition being treated, a question that has nothing to do with which machine looks more sophisticated. For plasmapheresis, in its approved indications, that calculation has been made using decades of collected data. For EBO2, it has not, because the small and largely single-group literature described above has not produced the kind of collected safety and outcome data that a real risk-benefit calculation needs. Ozone therapy is not FDA-approved to treat any condition, and federal regulations describe ozone as a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy [7]. Anyone considering either procedure should discuss it with a physician and can review local options at clinics offering these services.

Bottom line

Plasmapheresis and EBO2 share a superficial resemblance: both draw blood through a machine and return it. Plasmapheresis is a defined medical procedure with FDA-regulated equipment and evidence-graded indications built over decades of systematic review [2][3]. EBO2 borrows some of plasmapheresis’s vocabulary and equipment style without sharing its regulatory status or its evidence base [5][6]. Calling EBO2 “ozone dialysis” describes what the filter looks like, not what has been shown to happen inside it. Anyone offered EBO2 as an alternative to, or a gentler version of, plasma exchange for a diagnosed autoimmune or neurologic condition should ask their physician directly whether that substitution is supported by anything beyond the shared appearance of the equipment, since on the evidence assembled here, it is not.